Saturday 17 October 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
16.20
2.59
−13.78%
Follow OMER
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
64.68% | 2.21% | (62.24%) | (89.15%) | |
| (48.56%) | (1.11%) | 33.06% | 51.22% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,745.30% | (2.40%) | 70.38% | 136.19% | |
Average Days of Receivables |
0.00 | 0.00 | 48.92 | 79.95 | |
Free Cash Flow per Share |
(1.59) | (1.83) | (1.32) | (0.95) | |
Free Cash Flow |
(105.32) | (116.16) | (94.76) | (68.74) | |
Capital Expenditures |
(0.09) | (0.06) | — | (0.07) | |
| Other line items | |||||
Cash ROIC |
1,349.95% | (42.06%) | (45.38%) | (38.65%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 9.40 | 7.05 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.26 | 0.25 | |
Inventory Turnover |
— | — | 1.65 | 1.85 | |
Average Days of Payables |
0.00 | 0.00 | 1,542.48 | 1,229.79 | |
Days of Inventory on Hand |
— | — | 52.59 | 163.30 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.20 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 78.87% | 64.37% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 48.73% | 48.60% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 8.50% | 7.39% | |
Interest Coverage |
19.52 | 127.91 | (82.22) | (8.23) | |
Operating CF/Net income |
0.87 | 34.65 | (1.10) | (0.55) | |
Depreciation/Fixed assets |
(3.11) | (0.38) | 0.18 | 3.19 | |
Capex/Depreciation |
0.01 | 0.10 | 0.00 | (0.02) | |
Revenue per Share |
0.00 | 0.00 | 1.25 | 1.35 | |
Operating CF per Share |
(1.59) | (1.83) | (1.32) | (0.95) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates